October 01, 2025

A Statistical Study of Attention Deficit/ Hyperactivity Disorder, Attention Deficit Disorder, and Hyperactivity and Their Relation to Sleep-Disordered Breathing

Increasing better sleep can enhance a child’s success in school and may improve attention, behavior, and neurocognitive processes, which can contribute to the child’s future health.

Compendium

September 30, 2025

Positive Airway Pressure Therapy and Cardiometabolic Risk: Evidence from a Multicenter Registry

Sleep Apnea (SA) is a recognized risk factor for hypertension, cardiovascular disease, and metabolic dysfunction

Baptist Health South Florida

September 26, 2025

From Precision Medicine to Population Medicine

Audrey Greenberg shares how multi-omics, AI, and advanced therapies could transform the future of biopharma.

The Medicine Maker

September 23, 2025

Innovative Roswell Park Radiation Therapy Protocol in Lung Cancer to Be Highlighted at ASTRO Annual Meeting

Experts from Roswell Park Comprehensive Cancer Center will share the findings of a novel approach using radiation therapy to treat lung cancer at the American Society for Radiation Oncology (ASTRO) Annual Meeting Sept. 27-Oct. 1, 2025, in San Francisco.

Roswell Park Comprehensive Cancer Center

September 22, 2025

City of Hope Awarded $23.7 Million to Map Biomarkers in NSCLC

City of Hope® has been awarded an up to $23.7 million contract from the Advanced Research Projects Agency for Health (ARPA-H) within the U.S. Department of Health and Human Services. The grant will he...

The ASCO Post

September 22, 2025

CheckMate 77T: Nivolumab Maintains Quality of Life and Reduces Symptom Deterioration in Resectable NSCLC

“Maintaining quality of life during and after treatment is vital to long-term success, and these results show that perioperative nivolumab supports both survival and patient well-being,” said experts ...

The ASCO Post

September 18, 2025

Observation Outperforms Adjuvant Crizotinib for Resected ALK-Positive NSCLC

Adjuvant treatment with the first-generation ALK inhibitor crizotinib failed to improve disease-free survival outcomes over observation for patients with surgically resected ALK-positive non–small cel...

The ASCO Post

September 15, 2025

Is IFITM3 a Driver of Immunotherapy Response in SCLC?

New research has identified interferon-induced transmembrane protein 3 (IFITM3) as a critical regulator of immunotherapy sensitivity in SCLC, offering a promising new avenue for overcoming resistance ...

The ASCO Post

September 15, 2025

Tarlatamab and Anti–PD-1 Therapy as First-Line Maintenance for ES-SCLC

The DLL3-targeted bispecific T-cell engager agent tarlatamab demonstrated significant overall survival in combination with anti‒PD-L1 therapy of either atezolizumab or durvalumab as first-line mainten...

The ASCO Post